191 related articles for article (PubMed ID: 25421346)
1. New therapy targets resistant non-small-cell lung cancers.
Jenks S
J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421346
[No Abstract] [Full Text] [Related]
2. Commentary: highlights in NSCLC from the 15th World Conference on Lung Cancer.
Wakelee HA
Clin Adv Hematol Oncol; 2014 Jan; 12(1 Suppl 1):17-21. PubMed ID: 24852399
[No Abstract] [Full Text] [Related]
3. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
4. What new therapeutic targets exist for EGFR-mutant NSCLC?
Rosell R
Lancet Oncol; 2014 Oct; 15(11):1184-5. PubMed ID: 25175098
[No Abstract] [Full Text] [Related]
5. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC).
Belani CP; Goss G; Blumenschein G
Cancer Treat Rev; 2012 May; 38(3):173-84. PubMed ID: 21715100
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer.
De Pas T; Spitaleri G; Pelosi G; De Carlis L; Lorizzo K; Locatelli M; Curigliano G; Toffalorio F; Catania C; de Braud F
J Thorac Oncol; 2009 Jan; 4(1):138-9. PubMed ID: 19096323
[No Abstract] [Full Text] [Related]
7. Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer.
Bennouna J
Future Oncol; 2017 Sep; 13(21):1829-1833. PubMed ID: 28657354
[No Abstract] [Full Text] [Related]
8. [Consolidation therapy in advanced non-small cell lung cancer].
Duchnowska R
Pneumonol Alergol Pol; 2010; 78(6):439-44. PubMed ID: 21077036
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
11. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
12. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Costa DB
Lung Cancer; 2007 Aug; 57(2):251-2. PubMed ID: 17566601
[No Abstract] [Full Text] [Related]
13. EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Sattler M; Abidoye O; Salgia R
ScientificWorldJournal; 2008 Sep; 8():909-19. PubMed ID: 18836658
[TBL] [Abstract][Full Text] [Related]
14. A phase Ib, dose-finding study of erlotinib in combination with a fixed dose of pertuzumab in patients with advanced non-small-cell lung cancer.
Felip E; Ranson M; Cedrés S; Dean E; Brewster M; Martínez P; McNally V; Ross G; Galdermans D
Clin Lung Cancer; 2012 Nov; 13(6):432-41. PubMed ID: 22609229
[TBL] [Abstract][Full Text] [Related]
15. Three cheers for targeted therapy in non-small cell lung cancer... When we hit the target!
Codacci-Pisanelli G; Frati L; Mini E
J Chemother; 2011 Aug; 23(4):245-6. PubMed ID: 21803707
[No Abstract] [Full Text] [Related]
16. For investigational targeted drugs, combination trials pose challenges.
Goldman B
J Natl Cancer Inst; 2003 Dec; 95(23):1744-6. PubMed ID: 14652234
[No Abstract] [Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out?
Gandara DR; Gumerlock PH
J Clin Oncol; 2005 Sep; 23(25):5856-8. PubMed ID: 16043825
[No Abstract] [Full Text] [Related]
18. Newer opportunities in systemic therapy of lung cancer.
Rajan A; Gutierrez M; Giaccone G
Ann Oncol; 2008 Sep; 19 Suppl 7(Suppl 7):vii31-7. PubMed ID: 18790973
[No Abstract] [Full Text] [Related]
19. Problems involved in the clinical trials for non-small cell lung carcinoma.
Saijo N
Cancer Treat Rev; 2012 May; 38(3):194-202. PubMed ID: 21775064
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
